Su­cam­po bags rare dis­ease play­er Vtesse in $200M buy­out agree­ment

Just a lit­tle more than two years af­ter it was launched, the sin­gle-as­set biotech Vtesse is be­ing bought out by Su­cam­po for $200 mil­lion up front.

Vtesse spun out of the in­cu­ba­tor Cy­dan with a Se­ries A that even­tu­al­ly swelled to $42 mil­lion. The biotech used the cash to ad­vance a hu­man study in­to a new drug — which picked up a break­through drug des­ig­na­tion — for rare cas­es of Nie­mann-Pick type C1 dis­ease. And Rockville, MD-based Su­cam­po pledged back­ers a roy­al­ty stream on any mar­ket­ing rev­enue.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.